# psoriasis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3982
- Completion tokens: 16043
- Reasoning tokens: 
- Total tokens: 20025
- API requests reported: 
- Elapsed seconds: 153.063
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: DeepSeek

---
## 1. Overall biological interpretation

The psoriatic lesional-skin transcriptome is dominated by a coordinated upregulation of keratinocyte-derived inflammatory and structural programs. The most striking feature is not a single pathway but a multi-layered epithelial–immune circuit: keratinocytes overexpress IL-36 and IL-20 family cytokines, antimicrobial alarmins, cornified-envelope proteins, proteases/antiproteases, and metabolic enzymes, while simultaneously upregulating chemokines, myeloid/neutrophil markers, T-cell activation genes, and an immune-checkpoint ligand. The few downregulated genes are less functionally coherent, but include betacellulin (BTC) and several metabolism-related genes, suggesting loss of certain quiescent keratinocyte or xenobiotic-metabolism programs.

In aggregate, the data support a model in which psoriatic epidermis is both a source and a target of inflammation: epithelial-derived cytokines and alarmins amplify innate immune signals, recruit neutrophils and lymphocytes, and drive aberrant keratinocyte proliferation and differentiation. Many of the strongly upregulated genes are known psoriasis-associated effector molecules, but the interpretation below is based on the convergence of multiple genes rather than any single gene.

---

## 2. Core biological programs

### Program 1: Epithelial IL-36 / IL-20 cytokine amplification loop

- **Direction:** Upregulated in lesional skin  
- **Major supporting genes:** *IL36A* (log2FC 11.37), *IL36G* (5.68), *IL36RN* (3.01), *IL19* (7.58), *IL20* (5.67), *IL26* (4.36), *TNIP3* (7.28), *IRAK2* (2.08), *ZC3H12A* (3.85)  
- **Pathways:** Reactome “Interleukin-36 signaling”; Reactome “Interleukin-20 family signaling”; KEGG “Cytokine–cytokine receptor interaction”  
- **Explanation:** The simultaneous upregulation of IL-36 ligands and IL-20 family cytokines points to a keratinocyte-intrinsic inflammatory amplification loop. *IL36A* and *IL36G* are epithelial cytokines that act through the IL-36 receptor; *IL36RN* encodes a receptor antagonist, likely representing feedback. *IL19*, *IL20*, and *IL26* share IL-20 receptor subunits and are implicated in keratinocyte activation. *TNIP3*, *IRAK2*, and *ZC3H12A* are downstream NF-κB/innate-immune regulators that fit with IL-1/TLR/IL-36 signaling. The collective picture is an epithelial cytokine hub rather than a single cytokine effect.  
- **Strength/limitations:** Very strong statistical support from multiple independent genes with extremely low FDRs. Main limitations: bulk tissue cannot establish which cell type produces each cytokine, and the upregulation of *IL36RN* suggests an active feedback inhibitor, so ligand/antagonist balance must be interpreted cautiously.

---

### Program 2: S100 alarmin and antimicrobial peptide response

- **Direction:** Upregulated in lesional skin  
- **Major supporting genes:** *S100A7* (7.09), *S100A7A* (9.83), *S100A8* (7.73), *S100A12* (8.33), *DEFB4A* (11.18), *DEFB4B* (11.03), *DEFB103A* (5.76), *DEFB103B* (5.75), *PI3* (9.24), *TCN1* (8.04)  
- **Pathways:** GO “defense response to bacterium”; Reactome “Innate Immune System”; Hallmark “Inflammatory Response”  
- **Explanation:** These genes encode cationic antimicrobial proteins, β-defensins, and S100 alarmins. They are strongly expressed by stressed keratinocytes and act as both antimicrobial effectors and damage-associated molecular patterns that amplify inflammation via receptors such as TLR4 and RAGE. Their coordinate upregulation indicates an innate antimicrobial barrier response, consistent with the classic psoriatic phenotype of epidermal antimicrobial peptide overexpression.  
- **Strength/limitations:** Statistically overwhelming. However, this pattern is not unique to psoriasis; it can occur in atopic dermatitis, wound healing, or bacterial skin infection. The mRNA signal also does not reveal post-translational protein activity or tissue distribution.

---

### Program 3: Aberrant keratinocyte differentiation, cornified-envelope remodeling, and protease–antiprotease balance

- **Direction:** Upregulated in lesional skin  
- **Major supporting genes:** *SPRR2A/B/D/E/F/G*, *SPRR3*, *LCE3A*, *LCE3D*, *KRT6A*, *GJB2*, *GJB6*, *SERPINB3*, *SERPINB4*, *SERPINB11*, *SERPINB13*, *KLK13*, *TMPRSS11D*, *RHCG*, *FABP5*  
- **Pathways:** Reactome “Keratinization”; GO “cornified envelope”; KEGG “Pathways in cancer” is less specific; Reactome “Extracellular matrix organization” is partially relevant  
- **Explanation:** SPRRs and LCE proteins are structural components of the cornified envelope, and their strong induction indicates altered terminal differentiation with excessive/aberrant epidermal barrier formation. *KRT6A* is a wound-associated hyperproliferative keratin. *GJB2/GJB6* encode connexins involved in keratinocyte communication. The SERPIN/KLK/TMPRSS11D group reflects a coordinated protease–antiprotease program relevant to desquamation, scaling, and tissue remodeling.  
- **Strength/limitations:** Supported by many genes and consistent with psoriatic epidermal hyperplasia. However, the changes may partly reflect the increased proportion of keratinocytes in lesional skin rather than a uniform cell-intrinsic change in all keratinocytes.

---

### Program 4: Immune recruitment and T-cell/checkpoint activation

- **Direction:** Upregulated in lesional skin  
- **Major supporting genes:** *CXCL13* (5.89), *CXCR2* (2.70), *CD274* (3.44), *PRKCQ* (2.88), *ADAP2* (2.09), *HABP2* (4.19), *PLBD1* (2.08), *TCN1* (8.04)  
- **Pathways:** KEGG “Chemokine signaling pathway”; Reactome “PD-1 signaling”; GO “leukocyte chemotaxis”  
- **Explanation:** This module represents the immune-infiltrate side of the disease. *CXCL13* is a B-cell/follicular-helper chemokine; *CXCR2* is a chemokine receptor expressed by neutrophils and myeloid cells; *CD274* (PD-L1) can inhibit T-cell function; *PRKCQ* encodes PKC-θ, a critical T-cell activation kinase. The combination suggests a mixed immune environment containing both inflammatory effector cells and potential negative-feedback/checkpoint signals.  
- **Strength/limitations:** Multiple genes with strong statistical support. The biological interpretation is more complex because these genes may come from different cell types — keratinocytes, T cells, neutrophils, dendritic cells, or B cells. The co-occurrence of *CXCL13* and *CD274* does not imply a direct interaction.

---

### Program 5: Proliferative and metabolic rewiring

- **Direction:** Upregulated in lesional skin; selected downregulated genes may also reflect altered differentiation state  
- **Major supporting genes:** *KYNU* (4.42), *AKR1B10* (6.27), *AKR1B15* (5.23), *GDA* (5.90), *HPSE* (2.92), *WNT5A* (2.53), *CCNE1* (2.56), *RRM2* (2.72), *CDK5R1* (2.35), *ABCG4* (4.75); downregulated: *BTC* (−4.30), *CYP2W1* (−4.70), *UGT3A2* (−4.59)  
- **Pathways:** KEGG “Tryptophan metabolism” (*KYNU*); KEGG “Cell cycle” (*CCNE1*, *RRM2*); Reactome “Heparan sulfate/heparin metabolism” (*HPSE*)  
- **Explanation:** This program captures metabolic and proliferative adaptation. *KYNU* is a kynurenine-pathway enzyme that can modulate T-cell function and NAD metabolism. *AKR1B10* and *AKR1B15* are aldo-keto reductases involved in retinoid metabolism and oxidative-stress responses. *HPSE* degrades heparan sulfate and can release growth factors, promoting proliferation and remodeling. *CCNE1* and *RRM2* are direct cell-cycle/DNA-synthesis genes. The interpretation is that psoriatic keratinocytes are metabolically rewired toward proliferation and tissue remodeling.  
- **Strength/limitations:** Moderate statistical support from multiple genes, but the module is more functionally heterogeneous than the others. Some genes may be expressed by infiltrating immune cells rather than keratinocytes, and the downregulated genes are too few to define a coherent counterpart program.

---

## 3. Key genes and interaction modules

### 3.1 IL-36 ligand/antagonist module: *IL36A*, *IL36G*, *IL36RN*

- **Statistical direction:** Strongly upregulated; *IL36A* log2FC 11.37, *IL36G* 5.68, *IL36RN* 3.01.  
- **Role:** This is the most inflammatory cytokine-related module in the dataset. *IL36A* and *IL36G* are likely drivers of keratinocyte and immune activation; *IL36RN* is a natural antagonist.  
- **Gene-gene relationship:** Direct molecular relationship is established from prior biology: IL36A/IL36G bind IL-36 receptor, and IL36RN competitively antagonizes that receptor. The mRNA data alone do not prove the protein-level balance, but the coordinated upregulation is consistent with a ligand/antagonist feedback system.

### 3.2 IL-20 family cytokine module: *IL19*, *IL20*, *IL26*

- **Statistical direction:** *IL19* log2FC 7.58, *IL20* 5.67, *IL26* 4.36.  
- **Role:** These cytokines activate keratinocyte proliferation and immune crosstalk; they are a parallel epithelial inflammatory axis to IL-36.  
- **Gene-gene relationship:** *IL19*, *IL20*, and *IL26* share receptor subunits (IL20RA/IL20RB/IL10RB) and therefore represent pathway co-membership and receptor-sharing. They are co-expressed here, but no direct physical interaction between the cytokines is implied.

### 3.3 S100/defensin alarmin module: *S100A7*, *S100A7A*, *S100A8*, *S100A12*, *DEFB4A*, *DEFB4B*

- **Statistical direction:** Among the strongest upregulations in the dataset.  
- **Role:** Core antimicrobial/alarmin response; likely amplifies innate inflammation and recruits neutrophils.  
- **Gene-gene relationship:** Functional convergence rather than direct protein–protein interaction. *S100A8* and *S100A12* may act through shared receptors/co-receptors (e.g., TLR4/RAGE), and the defensins are part of the same innate antimicrobial program, but this dataset does not establish physical interactions among these proteins.

### 3.4 Cornified-envelope structural module: *SPRR2A/B/D/E/F/G*, *SPRR3*, *LCE3A*, *LCE3D*

- **Statistical direction:** Strongly upregulated, with *SPRR2A* log2FC 7.31 and *SPRR3* 7.18.  
- **Role:** Structural proteins of the cornified envelope; markers of aberrant keratinocyte terminal differentiation.  
- **Gene-gene relationship:** Pathway/structural co-membership. These proteins are substrates for transglutaminase cross-linking within the cornified envelope, so some direct protein cross-linking may occur, but that cannot be inferred from mRNA data.

### 3.5 Protease/antiprotease module: *SERPINB3*, *SERPINB4*, *SERPINB13*, *KLK13*, *TMPRSS11D*, *PI3*

- **Statistical direction:** Upregulated; *SERPINB3* log2FC 6.74, *SERPINB4* 9.12, *PI3* 9.24.  
- **Role:** Likely regulates desquamation, keratinocyte survival, and barrier integrity.  
- **Gene-gene relationship:** Indirect/putative functional relationship. SERPINs and PI3 are protease inhibitors, while KLK13 and TMPRSS11D are proteases; the balance between them may matter, but direct inhibitory pairs are not established by this dataset.

### 3.6 Metabolic enzyme module: *KYNU*, *AKR1B10*, *AKR1B15*

- **Statistical direction:** Upregulated; *KYNU* log2FC 4.42, *AKR1B10* 6.27, *AKR1B15* 5.23.  
- **Role:** Metabolic reprogramming in tryptophan/kynurenine and retinoid/aldehyde metabolism; may influence local immune tolerance and oxidative stress.  
- **Gene-gene relationship:** Co-expression and shared participation in broader metabolic rewiring, but no direct physical interaction is supported by the data.

### 3.7 Immune recruitment/checkpoint module: *CXCL13*, *CXCR2*, *CD274*, *PRKCQ*

- **Statistical direction:** All upregulated.  
- **Role:** Recruitment of immune cells and modulation of T-cell responses. *CXCL13* is a B-cell chemoattractant; *CXCR2* supports neutrophil/myeloid recruitment; *CD274* (PD-L1) can suppress effector T cells; *PRKCQ* is a T-cell activation kinase.  
- **Gene-gene relationship:** Co-occurring immune programs rather than a single interaction chain. Important: *CXCL13* binds CXCR5, not CXCR2; *CD274* binds PD-1; *PRKCQ* is intracellular. No direct physical interactions among these genes’ products should be inferred from this dataset.

### 3.8 Proliferation/remodeling module: *HPSE*, *WNT5A*, *CCNE1*, *RRM2*

- **Statistical direction:** Upregulated; *CCNE1* 2.56, *RRM2* 2.72, *HPSE* 2.92, *WNT5A* 2.53.  
- **Role:** Cell-cycle progression, DNA synthesis, and extracellular-matrix remodeling.  
- **Gene-gene relationship:** Indirect/putative. *HPSE* can release matrix-bound growth factors and may modulate Wnt signaling, but the link to *WNT5A*, *CCNE1*, and *RRM2* is not direct and requires functional validation.

---

## 4. Validation priorities

### Priority 1: Functional testing of the IL-36/IL-20 epithelial amplification loop

- **Classification:** Mechanistic hypothesis  
- **Why:** This is the strongest cytokine module in the data and is biologically coherent with keratinocyte-driven inflammation.  
- **Current evidence:** Multiple independent cytokine genes with extreme statistical significance; downstream signaling/regulatory genes are also upregulated.  
- **External evidence:** IL-36 signaling is strongly implicated in pustular psoriasis and skin inflammation; IL-20 family targeting has been explored for psoriasis. Conflict: IL-36 is more clearly central in generalized pustular psoriasis than in plaque psoriasis, and the data here do not identify the clinical subtype.  
- **Next step:** Use keratinocyte-organotypic cultures or imiquimod/IL-23 skin models to block IL-36R or IL-20R and measure downstream S100/defensin expression and neutrophil recruitment.  
- **Conclusion:** Supported hypothesis, not established causal relationship.

### Priority 2: Validate S100/defensin proteins as disease-activity biomarkers

- **Classification:** Biomarker  
- **Why:** These are among the most highly upregulated genes, and the proteins are secreted or released into extracellular space, making them suitable for protein-level measurement.  
- **Current evidence:** Strong mRNA upregulation of *S100A7*, *S100A7A*, *S100A8*, *S100A12*, *DEFB4A/B*, and *PI3*.  
- **External evidence:** Calprotectin and S100A12 are measurable in blood/tissue and correlate with inflammatory disease activity. Conflict: the markers are not psoriasis-specific and may overlap with other inflammatory skin diseases.  
- **Next step:** Multiplex ELISA or targeted proteomics in plasma and lesional/nonlesional skin from an independent psoriasis cohort, correlated with PASI and treatment response.  
- **Conclusion:** Supported hypothesis as a biomarker signature; not established as a diagnostic tool.

### Priority 3: Cell-type deconvolution and composition check

- **Classification:** Confounding or composition check  
- **Why:** Bulk skin transcriptomes include keratinocytes, fibroblasts, endothelial cells, T cells, neutrophils, dendritic cells, and other populations. Many of the top changes could reflect differences in cell proportions rather than expression-level shifts within a fixed cell type.  
- **Current evidence:** The dataset contains both epithelial structural genes and immune-cell genes, suggesting a mixed contribution.  
- **External evidence:** scRNA-seq studies of psoriasis show substantial changes in keratinocyte differentiation states and immune infiltrate composition.  
- **Next step:** Perform single-cell/single-nucleus RNA-seq on matched samples, or at least use computational deconvolution and IHC for key proteins (S100A12, CXCL13, CD274, KRT6A).  
- **Conclusion:** This is an interpretation safeguard; the biological conclusions above should be considered conditional until composition is accounted for.

### Priority 4: Determine the IL-36 ligand/antagonist protein balance

- **Classification:** Mechanistic hypothesis / therapeutic target  
- **Why:** *IL36RN* upregulation could mean the system is attempting to suppress IL-36 signaling, while the much larger fold increase in *IL36A* suggests ligand excess. The relevant biological outcome depends on protein concentrations and receptor occupancy.  
- **Current evidence:** mRNA imbalance favoring *IL36A/G* over *IL36RN*.  
- **External evidence:** Loss-of-function *IL36RN* mutations cause generalized pustular psoriasis, supporting IL-36 antagonism as protective. Anti-IL36R therapy is clinically relevant in pustular disease. However, drug availability alone is not evidence of efficacy in plaque psoriasis.  
- **Next step:** Quantify IL-36α, IL-36γ, and IL-36Ra protein in lesional skin and blood; test IL-36R signaling in patient-derived keratinocytes with and without IL-36RN.  
- **Conclusion:** Supported hypothesis for pathway involvement; therapeutic target remains exploratory for this specific disease context.

### Priority 5: Test the protease/antiprotease and cornified-envelope remodeling module

- **Classification:** Interaction / network hypothesis  
- **Why:** The coordinate upregulation of SERPINs, KLK13, TMPRSS11D, PI3, SPRRs, and LCEs suggests altered proteolytic processing of the cornified envelope, potentially explaining scaling and barrier dysfunction.  
- **Current evidence:** Many genes from this module are strongly upregulated with very low FDRs.  
- **External evidence:** Kallikrein proteases regulate desquamation, and SERPINB3/B4 are elevated in inflammatory skin diseases. Conflict: the exact protease–substrate relationships in psoriasis are not established, and SERPINs are also induced in other conditions.  
- **Next step:** Assay protease activity and cornified-envelope cross-linking in lesional skin; inhibit candidate proteases (KLK13, TMPRSS11D) in differentiated keratinocyte cultures and measure SPRR/LCE incorporation.  
- **Conclusion:** Exploratory hypothesis.

---

## 5. Evidence grounding

The interpretation above draws on several evidence types:

- **Direct statistical evidence from the input dataset:** log2FC, P values, and FDRs, which are extremely strong for many genes.
- **Pathway/ontology evidence:** Gene annotations for known cytokine signaling, antimicrobial peptide activity, keratinization, chemokine signaling, and cell-cycle pathways.
- **Protein interaction/regulatory evidence:** Established IL-36 receptor–antagonist biology for *IL36RN*; receptor-subunit sharing for IL-20 family cytokines. These are prior molecular relationships, not demonstrated by the mRNA data.
- **Disease-association evidence:** Many of the genes, especially *IL36A/G*, *S100s*, *DEFBs*, *SPRRs*, and *KRT6A*, are known to be associated with psoriasis or IL-17/IL-36-driven skin inflammation in the literature.
- **Expression/tissue-specific evidence:** Several genes are known to be keratinocyte-specific or immune-cell-specific, but this dataset alone cannot confirm their cellular origin.
- **Genetic/clinical evidence:** External evidence such as *IL36RN* loss-of-function mutations in pustular skin disease supports the IL-36 axis biologically.
- **Drug/therapeutic evidence:** Drugs targeting IL-36 or IL-20 pathways exist, but that alone is not evidence that these are effective therapeutic targets in the specific disease state represented by the current data.

The strongest conclusions are those supported by both independent statistical signals in the dataset and established pathway biology. However, the pathway annotations and disease-associated literature are not fully independent, since both rely partly on prior psoriasis/cytokine knowledge. Therefore, I have labeled conclusions as “established,” “supported hypothesis,” or “exploratory hypothesis” rather than treating any association as causal.

---

## 6. Limitations and alternative explanations

### 6.1 Tissue and cell-composition differences

Lesional psoriatic skin contains more keratinocytes, neutrophils, T cells, and Langerhans/dendritic cells than normal skin. Many of the observed “upregulations” may reflect increased abundance of particular cell types rather than increased expression per cell. This can be investigated by scRNA-seq, spatial transcriptomics, IHC, and computational deconvolution.

### 6.2 Disease severity, treatment, and clinical subtype are unknown

The table does not include patient metadata such as PASI, lesion location, disease duration, previous treatment, age, or sex. These variables can strongly affect gene expression and could alter the magnitude of the signals. Treatment exposure, in particular, may suppress or induce specific inflammatory and metabolic genes.

### 6.3 Broad overlap with other inflammatory skin conditions

Many of the top genes — S100s, defensins, SPRRs, SERPINs, keratins — are induced by IL-17/IL-22 cytokines and are not specific to psoriasis. The dataset may identify a shared epithelial stress response rather than a psoriasis-specific mechanism. Additional comparison with atopic dermatitis or wound healing would be needed.

### 6.4 Fold-change artifacts from low-baseline or unannotated genes

Several highly upregulated entries are pseudogenes, long intergenic noncoding RNAs, or genes with very low expression in normal skin (e.g., *VNN3P*, *LOC105376238*, *LOC105376239*, *LINC01206*). Their huge fold changes may be driven by near-zero baseline expression; no biological interpretation should be assigned to them without additional expression and functional validation.

### 6.5 Association versus causation and feedback ambiguity

The data establish correlative transcriptional changes only. For example, *IL36RN* upregulation could represent protective feedback, not part of the pathogenic driver, and *CD274* upregulation could reflect immune-inhibitory feedback rather than pure inflammation. Causal direction cannot be inferred from mRNA levels alone. Functional perturbations are required before labeling any gene or pathway as a disease driver or therapeutic target.

---

**Summary:** The current data strongly support a psoriatic epithelial–immune amplification state characterized by IL-36/IL-20 cytokine signaling, antimicrobial alarmin expression, abnormal keratinocyte differentiation, immune recruitment, and proliferative/metabolic rewiring. The most robust immediate conclusions are that these programs are active in lesional psoriatic skin. Whether they are causal, cell-type-specific, or therapeutically targetable requires further mechanistic, protein-level, and single-cell validation.
